{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"groups":[{"description":"This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).\n\nFludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.\n\nCyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.\n\nTotal Body Irradiation: TBI 200cGy on day -1 before transplant.\n\nHaploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion","id":"OG000","title":"Haploidentical Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Patients Experiencing Transplant Related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"Participants"}